Certainly, BGB324, due to its high selectivity for AXL, is the drug that has mainly produced significant results in terms of growth inhibition; in addition, it is the only specific AXL inhibitor to be involved in clinical trials for the treatment of several cancers. This evidence concerns the gene AXL and cancer.